An introduction from
our management

- Chairman's Statement

- Letter from the CEO

o1
Chiesi at a Glance

02
Positive Impacts
and Challenges

- Products and Patients
~ Processes

- Global Value Chain

- Corporate Citizenship

03

Chiesi’s contribution
to the UN Sustainable
Development Goals

04

Annexes

- Impact Report

- Data, Methodology
and GRI Content Index

Economics

Proportion of spending on local suppliers

In 2019, in Italy, Chiesi sourced 46.3% of its goods from national suppliers, leaving
a significant percentage for local suppliers, a positive impact on the communities
in which we operate. In other significant locations of the Group, around 75.6% of

Chiesi supplies were purchased locally.

 

    
  

  
  
 
   
 

Spending on local
suppliers - %

  

Country

 

Australia (Emerge Health Pty)

Austria (Chiesi Pharmaceuticals GMBH) 47 4
Bulgaria (Chiesi Bulgaria Itd) 95 9.
Czech Republic (Chiesi cz SRO) 83

2:

N/A
5
4.2
87.1
Hungary (Chiesi Hungary kft)
88.6
88.9
7.6
3
8

     

 

 

 

Romania (Chiesi Romania srl) eee eee
7
Slovakia (Chiesi Slovakia SRO) 91 9

ca

Belgium (Chiesi SA) 95 9

Brazil (Chiesi Farmaceutica Ltda.) 84 6.

China (Chiesi Pharmaceuticals Shanghai Co. Ltd) 99 9

tenet etsy fw —| |

France (Chiesi SAS) 62 777

Slovenia (Chiesi Slovenija d.o.0.)

 

 

 

 

France (Nh.Co) 78 Not available

 

Germany (Chiesi gmbh) 95

 

Greece (Chiesi Hellas Pharmaceuticals SA) 94

   
   

  

   
  
 
       
   
   
   
   
 

Italy (Chiesi Farmaceutici)

eae
Italy (Marco Antonetto) lo Not available

Mexico (Chiesi Mexico S.A. DE C.V.)

7 Not available
93.8

Netherlands (Chiesi Pharmaceuticals B.V.) 95

 

 

Pakistan (Chiesi Pharmaceuticals (Pvt) Ltd.) 97 Not available

 

Poland (Chiesi Poland SP Z.0.0.) 88 97.1

Russia (LLC Chiesi Pharmaceuticals) 86 Not available

 

Spain (Chiesi Espafia S.A.) 83 86.5

 

Sweden (Chiesi Pharma AB) 83 Not available

 

Switzerland (Chiesi S.A.) N/A

139

Annexes
